Raloxifene Effectiveness Unaffected by Kidney Disease
Increases bone mineral density, reduces vertebral fractures
THURSDAY, April 10 (HealthDay News) -- Raloxifene increases bone mineral density at the hip and spine better than placebo in postmenopausal women with osteoporosis and chronic kidney disease, and also reduces vertebral fractures, according to study findings published online April 9 in the Journal of the American Society of Nephrology.
Areef Ishani, M.D., from the University of Minnesota in Minneapolis, and colleagues analyzed data from a clinical trial that randomly assigned 7,316 postmenopausal women with osteoporosis and chronic kidney disease to placebo or one of two doses of raloxifene (60 or 120 mg/day). The women also received calcium and vitamin D supplements.
The researchers found that over three years, raloxifene treatment increased spine bone mineral density and was associated with a reduction in vertebral fractures, regardless of kidney function. Bone mineral density also increased at the hip, with a greater effect in patients with mild to moderate kidney disease. Placebo and raloxifene treatment had opposite effects on femoral neck bone mineral density in women with low baseline creatinine clearance. Adverse events were similar within each category of kidney function.
"In conclusion, raloxifene increases bone mineral density at both the hip and the spine and reduces the risk for vertebral fractures among individuals with chronic kidney disease," Ishani and colleagues write. "The effect of raloxifene on hip bone mineral density is greater among those with mild to moderate chronic kidney disease."